South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
The biotechnology sector witnesses another strategic maneuver as private equity firms GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices for $1.1 billion. Avid, an influential contract development and manufacturing organization (CDMO), specializes in
In today's rapidly evolving field of biomanufacturing, traditional methods often fall short of the rigorous demands for real-time data and consistent product quality. Laser Force Cytology (LFC) has emerged as an innovative, label-free technology that offers a transformative approach to
In recent developments, Celltrion USA has significantly expanded the availability of its subcutaneous treatment for Crohn's disease and ulcerative colitis, Zymfentra, now accessible to 26 million patients across the United States. This milestone achievement is a result of the company’s strategic
